Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.See webinar details
Dr. Geoffrey Hale Chief Executive Officer of mAbsolve Ltd., UK2 Talks
Geoff Hale trained as a biochemist at Cambridge. In 1980 he joined Herman Waldmann to research therapeutic antibodies. From this came the first humanised antibody, Campath, a powerful immunosuppressant and treatment for Chronic lymphocytic leukemia (CLL) and multiple sclerosis. In 1995, Herman and Geoff moved to Oxford and set up... read morea centre to manufacture monoclonal antibodies. The Therapeutic Antibody Centre supplied more than 25 new antibodies for clinical trials in over 5000 patients worldwide. In 2002 Geoff founded BioAnaLab, a service laboratory specialising in the analysis of biologics. In 2009 the company was acquired by Millipore and Geoff served as Chief Scientist until 2011. Now he works as a scientist, consultant, and company director, with interests in the development of antibodies and antigens for research, diagnosis, and therapy.